Erythropoietin as an independent prognostic factor in myelodysplastic syndromes
DOI:
https://doi.org/10.32471/exp-oncology.2312-8852.vol-43-no-1.15914Keywords:
anemia, erythropoietin, myelodysplastic syndromes, survivalAbstract
Aim: To assess the level of erythropoietin (EPO) in blood sera of patients with different subtypes of myelodysplastic syndromes (MDS) from different risk subgroups and to determine its prognostic role. Materials and Methods: EPO was measured by enzyme-linked immunosorbent assay in peripheral blood of 54 patients with different MDS subtypes according to the French–American–British (FAB) classification. The comparison group consisted of 15 healthy individuals. Complete blood count (hemoglobin, leukocyte and platelet levels) was determined and bone marrow cells were characterized morphologically. The overall and leukemia-free survivals were estimated by Kaplan — Meier method. Results: The level of ЕРО in MDS was reliably higher in comparison with healthy persons (p < 0.01, Mann — Whitney test). No statistically significant difference was found in serum EPO concentration between the groups of patients with low- and high-risk MDS (603.5 pg/ml vs 721.0 pg/ml; p > 0.05). In transfusion-dependent patients, the level of EPO was significantly higher than in other patients, which may be due to increased endogenous EPO secretion resulting from chronic hypoxia. A negative correlation was revealed between EPO level and Hb level as well as between EPO level and percentage of blast cells in bone marrow in high-risk MDS patients but not in patients with less aggressive variants of MDS. Instead, patients with low-risk MDS had a negative relationship between concentrations of EPO and tumor necrosis factor alpha (p = 0.06, Kendall’s tau test). No significant difference was found between EPO concentration in cases differing by bone marrow cellularity or the presence of cytogenetic abnormalities. An EPO concentration below 200 pg/ml was a predictor of shorter overall survival in patients with all MDS subtypes (p < 0.05, Mann — Whitney test). In patients with all FAB disease subtypes, there was no relationship between the leukemia-free survival and serum EPO concentration. Conclusion: This study shows that lower serum EPO level may be considered as one of the additional adverse prognostic factors in MDS patients.
References
Zhao ZG, Hu W, Yu HP, et al. Functional characteristics of mesenchymal stem cells derived from bone marrow of patients with myelodisplastic syndromes. Cancer Lett 2012; 317: 136–43.
Geyh S, Oz S, Cadeddu RP, et al. Insufficient stromal support in MDS result from molecular and functional deficits of mesenchymal stromal cells. Leukemia 2013; 27: 1841–51.
Kastrinaki MC, Pavlaki K, Batsali AK. Mesenchymal stem cells in immune-mediated bone marrow failure syndromes. Clin Dev Immunol 2013; 2013: 265608.
Vinchi F, Hell S, Platzbecker U. Controversies on the consequences of iron overload and chelation in MDS. Hemasphere. 2020; 4: e357.
Aggarwal S, Van de Loosdrecht AA, Alhan C, et al. Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implication for immunotherapy. Br J Haematol 2011; 153: 568–81.
Yang L, Qian Y, Eksioglu E, et al. The inflammatory microenvironment in MDS. Cell Mol Life Sci 2015; 72: 1959–66.
Raaijmakers MH, Mukherjee S, Guo S, et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Blood 2010; 464: 852–7.
Jelkmann W. Regulation of erythropoietin production. J Physiol 2011; 589: 1251–8.
Chen X, Eksioglu EA, Zhou J, et al. Induction of myelodysplasia by myeloid derived suppressor cells. J Clin Invest 2013; 123: 4595–611.
Barret AJ, Sloand E. Autoimmune mechanisms in the pathophysiology of myelodysplastic syndromes and their clinical relevance. Haematologica 2009; 94: 449–51.
Suzuki T, Meguro A, Yamamoto C. Distribution of serum erythropoietin levels in Japanese patients with myelodysplastic syndromes. Int J Hematol 2015; 101: 32–6.
Scheller J, Chalaris A, Schmidt-Arras D, et al. The pro- and anti-inflamatory properties of the cytokine interleukin-6. Biohim Biophys Acta 2011; 1813: 878–88.
Ganan-Gomez I, Wei Y, Starczynowski DT, et al. Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes. Leukemia 2015; 29: 1458–69.
Cluzeau T, McGraw KL, Irvine B, et al. Pro-inflammatory proteins S100A9 and tumor necrosis factor-α suppress erythropoietin elaboration in myelodysplastic syndromes. Haematologica 2017; 102: 2015–20.
Hedley BD, Allan AL, Xenocostas A. The role of erythropoietin and erythropoiesis-stimulating agents in tumor progression. Clin Cancer Res 2011; 17: 6373–80.
Oliva EN, Nobile F, Alimena G, et al. Darbopoetin alfa for the treatment of anemia associated with myelodysplastic syndromes: efficacy and quality of life. Leuk Lymphoma 2010; 51: 1007–14.
Santini V. Clinical use of erythropoietic stimulating agents in myelodysplastic syndromes. Oncologist 2011; 16: 35–42.
Harnan S, Ren S, Gomersall T, et al. Association between transfusion status and overall survival in patients with myelodysplastic syndromes: a systematic literature review and meta-analysis. Acta Haematol 2016; 136: 23–42.
Cortesão E, Tenreiro R, Ramos S, et al. Serum erythropoietin as prognostic marker in myelodysplastic syndromes. Acta Med Port 2015; 28: 720–5.
Nakazaki K, Nannya Y, Kurokawa M. Distribution of serum erythropoietin levels in lower risk myelodysplastic syndrome cases with anemia. Int J Hematol 2014; 99: 53–6.
Isufi I, Seetharam M, Zhou L, et al. Transforming growth factor — beta signaling in normal and malignant hematopoiesis. J Interferon Cytokine Res 2007; 27: 543–52.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
